Freshpet CEO’s 10b5-1 Sell Plan Signals Risk Over Reward Amid Legal Storm and Guidance Selloff

Freshpet's stock is in freefall, and the company is facing a fresh legal reckoning. The shares have already collapsed 60% in 2025, and they fell another 15.7% last week on weak guidance. This isn't just a market correction; it's a crisis of confidence. The latest blow came from the company's own forecast, where FY2026 EBITDA guidance of $205M–$215M came in well below the $226.2M consensus, overshadowing a beat on quarterly earnings and a historic manufacturing upgrade. The stock now trades around $58.93, far below the Street's mean target of $87.31.

Adding to the turmoil, a second legal probe has been launched. In March 2026, the Pomerantz Law Firm announced a new investigation into claims on behalf of investors of Freshpet, focusing on potential securities fraud. This follows a similar probe initiated in October 2025, signaling persistent regulatory and legal overhangs. The company is being investigated for whether it and its officers engaged in unlawful business practices.

Against this backdrop, the core question for any investor is about alignment. The CEO, William Cyr, has not sold any stock since 2021. Yet, he has filed a 10b5-1 plan to sell shares. This creates a clear disconnect. A 10b5-1 plan is a pre-arranged trading strategy designed to avoid accusations of insider trading, but it also signals a lack of skin in the game at a time when the stock is tanking and the company is under investigation. When the smart money is looking for a reason to stay, the CEO's own plan to exit suggests he sees the risk as outweighing the potential reward.

Insider Skin in the Game: The CEO's Planned Exit

The CEO's own plan to sell shares is the clearest signal of where his skin in the game is. Billy Cyr has filed a 10b5-1 plan to exercise options and sell shares to cover taxes and estate planning. The catch is timing: the plan cannot execute until after the company reports its fourth-quarter results in February 2026. That means he is scheduled to sell into a period of known weakness, right after the company delivered a guidance selloff.

His family and trusts hold a significant block of 1.3 million shares, representing 2.7% of the company. This is not a trivial amount. The plan is to sell shares from these options, which expire in September 2026, but the timing suggests a lack of alignment. While the company posted strong 2025 results-with net income more than doubling to $139.1 million-the CEO is preparing to exit a portion of his stake. He claims he has never sold a share and will retain at least 350,000 shares, but the pre-arranged plan to sell into a crisis period speaks volumes.

The bottom line is that the smart money is looking for conviction. When a CEO files a 10b5-1 plan to sell during a legal probe and a guidance collapse, it often signals that the insider sees the risk of holding outweighing the potential reward. It's a classic move to monetize options before they expire, but it's a move that public investors cannot easily replicate. In this setup, the CEO's planned exit is a red flag, not a vote of confidence.

Institutional Accumulation vs. Retail Panic

The retail panic is clear, but what about the smart money? The stock's 52-week range of $46.8 to $89.9 shows extreme volatility, a magnet for both fear-driven selling and opportunistic buying. The question is which side is winning.

The institutional narrative seems to be one of selective selling. The company's own 2026 guidance is a major overhang. Management is projecting net sales growth of 7% to 10% and EBITDA of $205M–$215M, both well below Street expectations. This cautious outlook, delivered right after a historic manufacturing upgrade and a beat on quarterly earnings, likely triggered a wave of institutional reassessment. The smart money often sells into guidance misses, especially when they come from a company already under a legal microscope.

Yet, there's a counter-current. The company is investing heavily for the long term, with $148.2 million in capital expenditures in 2025 and a potential $20-50 million increase in 2026. This capital intensity, focused on new technology and expansion, suggests insiders believe in the underlying business model. The disconnect is that institutional accumulation often follows a price drop, not precedes it. The stock is down 60% in 2025 and another 15.7% last week, creating a potential dip-buying opportunity. But the guidance selloff may have been too sharp, too fast for many funds to see value yet.

The insider trading data tells a mixed story. While the CEO is preparing to sell, other executives have been more active. Since 2021, there have been 93 insider trades at Freshpet, with more shares sold than purchased. However, the most recent trade was a purchase of 630 shares reported on February 25, 2026, just days after the guidance miss. This suggests some insiders are still willing to buy at these levels. It's a small signal, but it shows the skin in the game isn't entirely absent.

The bottom line is that institutional accumulation is likely muted for now. The legal probe and the guidance selloff create too much near-term risk. Smart money is waiting for clearer signs of a turnaround before committing capital. For now, the retail panic is driving the price, while the smart money is on the sidelines, watching.

Catalysts and What to Watch

The thesis of a leadership disconnect hinges on two near-term events. First, watch for the execution of the CEO's 10b5-1 plan. The plan is set to activate after the company reports its fourth-quarter results in February 2026, which has already passed. The key will be the size and timing of the sale. The plan involves selling shares from a block of 1.3 million shares, representing 2.7% of the company. A large, immediate sale of this block into the current crisis would confirm the CEO's lack of skin in the game. A smaller, staggered sale might be less telling, but the mere existence of the plan is a signal.

Second, monitor the Q1 2026 earnings report for any deviation from the cautious 2026 guidance. Management has set a low bar with 2026 EBITDA guidance of $205M–$215M, well below the Street consensus. If the company beats this already-low target, it could signal that management's view is improving. A miss, however, would validate the market's pessimism and likely trigger another selloff.

Finally, track any insider buying by other executives. The most recent trade was a purchase of 630 shares reported on February 25, 2026, just days after the guidance miss. This is a small but bullish signal against the CEO's planned exit. If other insiders follow suit, it would suggest some conviction remains at the operational level. If the buying stops, it would reinforce the narrative that the smart money is waiting for a clearer turnaround before committing capital.